

Research article

Ebola Virus A Bioterrorism: Brief Review

Anjali Rao¹ and Budhayash Gautam^{2*}

¹PhD Research Scholar, Department of Computational Biology & Bioinformatics,
 Jacob School of Biotechnology and Bioengineering,
 Sam Higginbottom University of Agriculture,
 Technology and Sciences, Allahabad-211007, India.

^{2*} Assistant Professor, Department of Computational Biology & Bioinformatics,
 Jacob School of Biotechnology and Bioengineering,
 Sam Higginbottom University of Agriculture,
 Technology and Sciences, Allahabad-211007, India.

*Corresponding Author: budhayash.gautam@shiats.edu.in,
budhayashgautam@gmail.com, Mob: +91-9451427316

ABSTRACT

Ebola virus sickness described as “one of the world’s most virulent diseases” by WHO was once popularly diagnosed as Ebola hemorrhagic fever in the past. It is commonly viewed an intense and deadly sickness when human beings are concerned. EVD outbreaks have proven to have a very excessive fatality rate ranging from 50 - 90% with a noted incidence mainly seen shut to the tropical rainforests of some distance of villages in Central and West Africa. The virus is transmitted to humans from wild animals and interior the human neighbourhood through human-to-human contact. The natural host for Ebola virus is now no longer, but conclusively identified on the other hand the most possibly host seems to be the fruit bats. Five subspecies of Ebola virus are diagnosed until date, with Zaire Ebola virus being the most aggressive of all varieties and recording up to 90% mortality. All Ebola types are exceedingly contagious and therefore have been classed as Category A priority pathogens by using WHO. Severely sick sufferers warrant intensive aid therapy. Medical people working in affected areas choose to undertake large measures to prevent contracting the disease. Till date, no specific anti-viral remedy has set up effectiveness in Ebola virus infection. Also, no vaccine for use in humans is yet permitted by using the regulatory bodies. If Ebola was really misused as an organic weapon, it ought to be a serious threat. Idea at the urging of this article is to quickly consider the data and present recent updates on the Ebola virus, its pathogenesis and feasible hopes for treatment.

Keywords: EVD, hemorrhagic, Epidemiology, Pathogenicity.

INTRODUCTION

In this universe, so many microorganisms are present, which are pathogenic in nature like viruses, bacteria, fungi, parasites, etc. in which viruses are those infectious particles that cause many serious illnesses and sometimes non treatable diseases basically for humans and also other animals; plants etc. [1- 3]. Viruses don’t have their own metabolic machinery for replication that’s why they depend on the host. Genomic configuration of viruses either DNA or RNA as clearly mentioned in Figure 1 [4].




Figure1: Classification of viral Genome

Two very important actions occur that time when virus infects a new host cell. One is that production of proteins/enzymes (virion proteins) and second one is viral replication. From the ancient history of viruses so many diseases caused by SSRNA viruses like influenza, common cold, SARS, polio etc. Every group of viruses assembled them in different ways because of differences in their genomes [5, 6]. Ebola Virus genome falls in single strand negative sense RNA. SS-RNA viruses have genetic material as RNA (ribonucleic acid). Based on polarity on RNA these RNA viruses classified into two sub-classes one is negative sense and other is positive sense. The basic difference behind between them is that positive sense RNA exact similar to the mRNA so this can be translated into the host cell but in negative sense RNA is complementary to mRNA so firstly change into the positive sense with the help of RNA Polymerase than translated [7, 18]. All world of viruses have different assembly formation which are mentioned in Figure 2.




Figure 2: Different types of viruses have different mode of assembly formation

The viruses live occurs so many years in inactive forms and when they found accurate host so proliferate themselves and infect so many classes of vertebrates, non-vertebrates and

plants. Now a day's so many viruses are rising and cause serious illness in humans and other vertebrates like EBOLA virus [8]. Ebola is a lethal virus that causes Ebola hemorrhagic fever (EHF) mostly in humans. It is a zoonotic disease that means infect both humans and nonhuman primates (antelopes, monkeys, gorillas, and chimpanzees). The transmission of virus occurs through wild animals to humans and then human to humans via infection [9]. The fatality rate of EV depends on their strains, but till now recorded fatality rate around 25 to 90%. Ebola spread firstly in West African countries. Ebola virus first casewas reported in 1976 in the Democratic Republic of the Congo. The natural reservoir host of Ebola virus remains unknown [8, 9]. However, on the basis of evidence and the nature of similar viruses, researchers believe that the virus is animal-borne and that bats are the most likely reservoir. Four of the five virus strains occur in an animal host native to Africa [10].

CLASSIFICATION

According to an International Committee of

taxonomy virus (ICTV), Ebola belongs to the Filoviridae family. There are five subtypes of Ebola virus; Zaire Ebolavirus, Sudan Ebolavirus, Tai Forest Ebolavirus, Bundibugyo Ebolavirus and Reston Ebolavirus, first four cause human to human infections and the fifth

one is cause nonhuman primates, but not found in humans [10, 11]. Zaire strain is more lethal than others. The first outbreaks of Zaire strain come in notice in 1976 in Yambuku and this is deadliest viral strain which have 80- 90 % mortality rate. Sudan strain is originated in Nzara, Sudan in 1976. Firstly SEBOV notice in cotton factory workers in Sudan [12]. Mode of infection/ transmission still unknown for SUDV and their fatality rate is average (41- 65%). The first outbreak of BDBV in Uganda in 1976 and their fatality rate is 30%. TAFV traced in Africa, where African chimpanzees broadly infected. First case of RESTV noticed in Virginia, where monkeys were infected [13].

15]. Nucleocapsid protein (NP), viral proteins VP35 & VP30 and L these four are required for replication and transcription of Ebola virus. Rest of proteins like GP, VP40 and VP24 are associated with virus membrane for the formation of virions [16]. Secreted glycoprotein (sGP) does not take part in viral replication alternatively is secreted from infected cells. It types a dimeric protein that interacts with neutrophils by using mediating neutrophil binding either immediately or circuitously thru CD16b [17, 18]. Neutrophil binding interferes with the signalling of neutrophils and aids the virus to stay away from the host immune machine by inhibiting early steps of neutrophil




Figure 3: Classification of Ebola virus with their lethal rate


GENOME ORGANIZATION AND EBOLA VIRUS PROTEINS

The genome of EV (Ebola virus) and MV (Marburg Virus) are around 19 Kilobase Non segmented (-) SSRNA as clear out in Figure 4 [11]. Virions size approximately is 970 nm L, 80 nm D. The entire length of the genome from 3' to 5', seven proteins are found which is helping in replication and transcription of the virus [14,

activation which by and large supports viral clearance. Further, neutrophils serve as carriers to disseminate the virus at some point of the whole physique to locations such as lymph nodes, liver, lungs, and spleen [19, 20]. Thus, sGP alters immune response by using inhibiting activation of neutrophils, whilst transmembrane GP might also make contributions to hemorrhagic fever signs with the aid of focused on the virus to the cells of the reticulo

endothelial network and the lining of blood vessels [21, 55].

Figure 4: Genome organization of Ebola virus



HIJACK MECHANISM OF EV

Most of the time ZAIRES EV infect humans and vertebrates. Their virulence mechanism firstly harms immune system, then attacks on the vascular system of the body as shown in Figure 5

dendritic cells [27]. These dendritic cells are passing a signal to T-cells from destroying the infected cells [28, 29]. After this attack on

macrophage cells of immune system. In last phase its attack on vascular system (endothelial cells). Then leakage of blood from blood vessels [30- 33].




Figure 5: Hijack mechanism of Ebola Virus

[22- 24]. From past to present (1976 to 2016), it's a challenge for researchers/scientists that how EV hijack the machinery of the host and how's that possible that to stop spreading in the whole body [25, 26]. Firstly Ebolavirus attack on


LIFE CYCLE OF EBOLA VIRUS

Figure 6, showed the whole life cycle of EBOV follows six sequential steps such as attachment

of virus, entry of viruses, transcription, replication, budding, spreading of virions [33-35]. In the attachment of viruses on the host cell surface so many receptors are identified to help with attachment and entry into host cell these are β 1 receptor, DC-SIGNR (dendritic cell specific intercellular adhesion molecules DC-SIGN related) & and DC-SIGN [36, 37]. It's also use different locations for entry into the host cells. For the entry of the virus takes place mostly two common processes that are Macropinocytosis and clathrin-mediated. Polarity behaviour of RNA, these RNA viruses classified into two sub-classes, one is negative sense and other is positive sense [38-41]. The basic difference behind between them is that positive sense RNA exactly similar to the mRNA so this can be translated into the host cell but in a negative sense RNA is complementary to mRNA so firstly change in the positive sense with the help of RNA Polymerase than translated. In the transcription process its form seven monocistronic mRNAs molecules with conserved start & stop codons [42- 46]. The process starts with the attachment of the

polymerase complex for a single site at leader region. The polymerase moves along the RNA template and transcribes the individual genes in their 3' to 5' order [47-49]. The newly formed proteins such as capsids and envelope which is associated to the host cell's plasma membrane; via which budding occurs and destroying the cell. These virus components of the cellular ESCRT (endosomal sorting complex required for transport) system to mediate host-assisted viral budding [50- 55]. SCRT complexes are normally used by the cell for biological functions involving membrane remodelling, such as intraluminal vesicle formation, autophagy or terminal stages of cytokinesis. The ESCRT family consists of ESCRT-0, ESCRT-I, ESCRT-II, which are primarily involved in cargo sorting and membrane deformation, and ESCRT-III which cleaves the bud neck from its cytosolic face. In the last step, VP24 disassembles the complex. Finally, the mature virions released and infect healthy cells of the body [55- 61].

Figure 6: Life cycle of Ebola Virus



TRANSMISSION OF EBOLA VIRUS

The actual natural reservoir host of Ebola virus nonetheless remains uncertain. On the foundation of available evidence and nature of comparable viruses, researchers trust that this virus is animal borne (zoonotic) and is definitely dependent on its hosts for replication and common survival.

Birds, arthropods and flowers are considered to be the viable reservoirs of Ebola virus, but it is now not, but conclusively established whether these are major reservoirs or intermediate reservoirs getting contaminated from the most important reservoirs. Bats appear to be the most in all likelihood reservoirs as there are hardly ever any medical symptoms that can be located in them.

In a currently conducted scan that protected 24 plant species and 19 vertebrates inoculated with Ebola virus, results showed bats to be infected, carrying and spreading the sickness [12,25]. Different fruit bats (*Epomopsfranqueti*, *Hypsignathusmonstrosus*, and *Myonycteristorquata*) have been observed to raise the virus except displaying any signs and symptoms of the disease. Of the 5 considered subtypes of Ebola virus, 4 sorts are acknowledged to dwell in an animal host which is native to Africa. Spread of Ebola virus is recognized to show up via contact with contaminated animals or humans; most likely, via direct contact of broken pores and skin or unprotected mucous membranes with virus-containing physique fluids.

Animal to human transmission takes location via contact with meat or body fluids of the contaminated animal. EVD suggests no sexual predilection, but guys and female differ with recognize to the manner in which the direct publicity can occur [62, 88]. Men, owing to their nature of work exposure in forest and savanna regions, may additionally additionally be at an accelerated danger of obtaining an important infection even as gathers "bush meat" (primate carcasses) for food, as appropriate as from unknown vectors. Infection amongst people can transmit through physical contact with

contaminated pores and pores and skin or bodily fluids such as blood, feces or vomit [89].

Ebola virus has moreover been detected in saliva, mucus, urine, and semen and breast milk. Male survivors might also additionally be in a role to transmit the contamination with the aid of skill of semen for almost two months. Routes of entry are open wounds, abrasions and cuts. The 'hot virus' as it so named can also moreover get transmitted via conjunctival, nasal and oral exposure.

In saliva, it has been determined most frequently at some point of the extreme stage of illness. Infected sufferers are no longer regarded communicable prior to onset of symptoms, i.e. throughout the incubation period of the virus. Risk of transmission is also very low in the course of the early onset of symptoms [31, 90]. However, there is an increase in communicability with every subsequent stage of illness with maximum chances of infection in later stages [92].

Cases continue to stay communicable as long as blood and body fluid secretions incorporate the virus, i.e. throughout the convalescence period, earlier than restoration and in the course of the post-mortem period. Ebola virus does not show any airborne transmission, but may additionally inadvertently spread by means of droplets that are coughed or sneezed from a sick person. Subsequently, these droplets may additionally enter the eyes, nose, or mouth of any other character who is less than two meters away. Strategies therefore be undertaken to decrease aerosol generation in aerosol producing clinical procedures [95].

Due to this practicable characteristic of the virus, it has also been labelled as a fairly possible agent of bioterrorism. Indirect transmission from surfaces or objects beforehand contaminated via blood or bodily fluids is a possibility, however the risk of transmission via this approach is low.

Medical employees are at a high chance of contracting the ailment especially when fabulous non-public protective equipment is not on hand or improperly used.

Hospital obtained infections are probable when needles are reused and enough containment measures are no longer practiced [98]. In Figure 7, clear out the different mode of transmission of Ebola virus.

cases. In the later stages of illness, sufferers may additionally suffer from profuse vomiting and diarrhoea, which unchecked may want to result in severe extent depletion, electrolyte imbalance and shock. Symptoms of EV infection earlier




Figure 7: Different mode of transmission of Ebola virus

SIGN AND SYMPTOMS OF EBOLA VIRUS INFECTION

In Figure 8, Ebola virus time duration mentioned in which the sickness has been frequently deadly in people and commonly runs its direction from 14 to 21 days. Its incubation duration is normally 8 to 10 days, however, can differ between 2 and 21 days [15]. Infection at the beginning provides with unexpected nonspecific influenza-like signs characterized by means of fever, fatigue, headaches, joint, muscles and stomach pain. Besides these, gastrointestinal signs and symptoms like stomach discomfort, nausea, vomiting, diarrhoea and loss of urge for food are also frequently seen. Other less frequent signs and symptoms include: sore throat, chest pain, hiccups, dyspnoea and challenge in swallowing. Presentations on pores and skin can also be in the shape of a maculopapular rash in about 50%

than the development into bleeding phase are very comparable to those of malaria, dengue fever or different tropical fevers and consequently warrant close monitoring for the duration. Bleeding segment commonly set in 5 to 7 days after the onset of first symptoms as clearly mentioned in Figure 9. In advancing stage of illness, the virus starts offevolved focused on microvascular endothelial cells, ensuing in loss of vascular integrity and leakage of blood [15]. Subsequent inner and subcutaneous bleeding manifests as hemorrhages beneath the pores and pores and skin regarded as petechiae, purpura, ecchymoses and haematomas in particular spherical needle injection or puncture sites. Bleeding from mucous membranes like gums, nose, gastrointestinal tract and vagina have moreover been reported. Within addition development of infection, sufferers begin to exhibit severe bleeding and coagulation abnormalities such as gastrointestinal bleeding (vomiting or coughing

up blood and/or blood in the stool), rashes and hematological irregularities like lymphopenia and neutrophilia. Liver damage related with big viremia leads to disseminated intravascular coagulopathy. Infected sufferers each so often showcase symptoms of circulatory machine involvement, such as impaired blood clotting [31]. On the whole, bleeding is typically indicative of horrible prognosis as hypotensive shock ensuing from blood loss due to diffuse bleeding commonly outcomes in death. In the match of non-restoration of a contaminated person, multiple organ failure contributing to death can be expected within 7 to sixteen days (usually between days eight and 9) after first signs and symptoms as mentioned in Figure 9. The mortality rate is as excessive as 90% in EVD. Usually, if the affected individual is successful to survive one week publish onset of symptoms, restoration has been rapid and complete[63].

Figure 8: Incubation period of Ebola virus





Figure 9: Symptoms of Ebola virus



DIAGNOSIS OF EBOLA VIRUS INFECTION

The diagnosis is very difficult of Ebola infected patient because it is very difficult to discriminate between and other infectious disease likes fever, malaria, typhoid and meningitis, etc. Ebola virus notice by the blood after three days of infection when body temperature rises. Some laboratory test available in the laboratory, but it depends on the time of infection [3, 64].

- In early days of infection
 - ❖ ELISA(Antigen capture ELISA)& IgM ELISA
 - ❖ PCR (polymerase chain reaction)
 - ❖ Sometimes isolation of virus
- In middle stage of infection
 - ❖ IgM/IgG Abs (antibodies test)
- In last stage
 - ❖ Immunohistochemistry test
 - ❖ Virus isolation
 - ❖ PCR

VACCINES OF EBOLA VIRUS

Despite ongoing research in this field, none of the antiviral entrepreneurs or vaccines for Ebola virus are in modern times accepted for human use via skill of the regulatory bodies. Currently accessible vaccines are nonetheless experimental and require full checking out for safety and efficacy in humans. Promising vaccines present process medical trials are these that are derived from adenoviruses, Vesicular Stomatitis Indiana Virus or virus-like particles as these are nicely regarded to render safety in nonhuman primates [69- 72]. This time in vaccine development researchers is based on the use of DNA, DNA prime/adenovirus boost, and also recombinant proteins. Gene-based vaccines development also attractive in this field [73]. Amongst the a wide variety of gene-based vaccines, use of bare plasmid DNA to direct synthesis of immunogens internal the host cells have proven successful software in animal models. Genetic immunization with plasmid DNA used to be developed in a guinea pig model and proved the first profitable vaccine for Ebola virus [74, 75]. A three plasmid DNA vaccine encoding envelope glycoproteins from Zaire and Sudan virus as well as nucleoprotein has additionally mounted correct tolerance and immunogenicity in segment 1 human trials [76, 78]. Priming boosting immunization the usage of mixture of DNA immunization and boosting with adenoviral vectors encoding viral proteins has proven technology of cellular and humoral immunity in cynomolgus macaques. Dramatically elevated immune responses, with a 30 fold or greater enlarge in antibody titer have been reported [80]. All vaccinated animals persevered to be asymptomatic for 6 months with no detectable virus after the preliminary challenge [81]. Recently, profitable improvement of a vaccine towards Ebola in mice used to be reported. Vaccines based on extra than one dose, might also know now not be practical in the direction of outbreaks owing to lesser time reachable for deployment of vaccines and moreover elevated costs. Immunization taking six months or longer impedes the counter-epidemic use of vaccines as a result necessitating the improvement of a

vaccine that has a faster onset of effectiveness [82]. In 2009, an experimental vaccine was made and tried by using researchers at Canada's country wide laboratory in Winnipeg to preemptively deal with a German scientist who may additionally have been infected with Ebola virus in the route of a lab accident [83].

PROPHYLAXIS AND PREVENTION OF EBOLA VIRUS

Despite the reality that a range of experimental redress for EVD are underneath study, no special therapeutic dealers are recognized to exist for treating or stopping Ebola virus infections [28]. Treatment for EVD is in unique in particular primarily based on supportive care remedy which consists of balancing fluids and electrolytes to counter dehydration given via either oral or intravenous route, administering anticoagulants early in infection to prevent or control disseminated intravascular coagulation, administering procoagulants late in contamination to manipulate bleeding, protecting oxygen status, managing nausea, fever and pain (avoid the use of aspirin or ibuprofen to limit chance of bleeding), prescribing medicinal pills to treat secondary bacterial or fungal infections and minimizing invasive techniques [84]. Treatment instituted at an early stage will increase chances of affected person survival. Therapeutic entrepreneurs below consideration for remedy or prevention of EVD encompass the followings

- ❖ Estrogen receptor pills like clomiphene and toremifene
- ❖ Favipiravir
- ❖ S-adenosylhomocysteine hydrolase (Nucleoside inhibitors)
- ❖ Human interferon alfa-2
- ❖ Human-derived convalescent immune globulin preparations
- ❖ Human mAbs for GP of Ebola virus
- ❖ DNA vaccines expressing for GP & nucleocapsid protein of Ebola virus

In the United States, FDA's animal efficacy rule can be used in aggregate with section I scientific trials to exhibit off real searching safety for an experimental, unapproved drug and to achieve permission for treating human beings

contaminated with the aid of Ebola with the drug underneath the extended get admission to utility. This rule exists because the regular course for making an attempt out the safety and efficacy of pills is now not possible for illnesses brought on by way of way of risky pathogens or toxins [85]. FDA allowed the following drugs to be used in human beings contaminated with Ebola below these applications in the course of the 2014 outbreak

- ❖ ZMapp is a mAb
- ❖ TKM-Ebola -RNA interference drug
- ❖ Favipiravir (a drug generic in Japan for stockpiling in the direction of influenza pandemics)

All viable measures should be undertaken to reduce exposure to viruses and forestall transmission in a health care setting. The following skill should be adopted [64, 86]

- ❖ To avoid direct contact with body fluids (such as vomits, urine, saliva etc.)
- ❖ Destroy those elements which are infected with Ebola patients, such as bed sheets, clothes, and medical instruments
- ❖ Avoid funeral & direct contact with dead body
- ❖ Avoid eats raw meat of animals
- ❖ When feel flu like symptoms, contact to a doctor
- ❖ Patient transportation by only one route not publically
- ❖ Focus on environment cleaning on a regular basis
- ❖ Focus on patient education for their prevention

EPIDEMIOLOGY

Ebola infection disperses in Africa, where it regularly drives extensive episodes of intense hemorrhagic fever with a high casualty rate [87, 88]. The principal instance of filovirus hemorrhagic fever accounted for in 1967 in Germany and the previous Yugoslavia, and the causal operator was recognized as Marburg infection. From that point forward, 12 comparable instances of hemorrhagic fever were depicted in 1976 from flare-ups in two neighbouring areas: first in southern Sudan and consequently in northern Zaire. This strain

acquired three added epidemics in the areas of Nezara, Sudan in 1979 [89]. An unknown causative abettor was abandoned from patients in both outbreaks and called Ebola virus afterwards a baby river in northwestern DRC. These two epidemics were acquired by two strains of EV, Sudan Ebola virus (SEBOV) and Zaire Ebola virus (ZEBOV) [90, 91]. Outbreaks of ZEBOV, SEBOV and BEBOV hemorrhagic agitation action intermittently in Africa and are associated with added than 90% of case-fatality rates [92]. Tai Forest virus (TAFV) was empiric in an infected ethnologist who acclimated to work in the Tai Forest in Côte d'Ivoire in 1994 in Africa. Later it was articular that this is anew apparent virus had the similar aspect of Ebola hemorrhagic agitation as the added two Ebola strains [93]. In 1994 a catching was primarily appear as a yellow fever outbreak in 44 cases with 28 deaths in Gabon. Later studies suggested that it was due to Ebola virus attack. Gabon was attacked alert by Ebola virus in 1996. The first beginning began in February and out of the 37 cases 21 died. The additional catching was from July to December and 40 deaths were appear a part of the 52 identified cases [94]. In 1995 in Kikwit, EBOV again emerged and affect large area of Africa. The presence of Zaire Ebola Virus (ZEBOV); Democratic Republic of the Congo in 1995 and 231 people died out of 300 afflicted people. Similar isolates were also observed during the beginning of this agitation in cynomolgus macaques in Texas, Alice and the Philippines in 1996 [95]. The 2nd beginning of the Sudan Ebola virus (SEBOV) catching was empiric in 2004 in Yambio and fresh in Sudan. A typical strain of Ebola virus called Bundibugyo Ebolavirus was articular during a beginning of viral fever in the Bundibugyo commune of western Uganda and after on in equatorial regions of Africa in 2007-2008. The Bundibugyo Ebola virus beginning to acquire a lower rate of deaths than did the Sudan Ebola virus beginning in Gulu and Sudan. Uganda admiral of health (UMOH) declared deaths of 39 bodies in this beginning, in the Bundibugyo commune [96]. At the end of August 2014, WHO was notified about addition, a stringent

beginning with similar observations of Ebola viral strain with 74% mortality rate in the belt of Boende town, Equator diocese of western democratic republic of Congo. It was the seventh Ebola beginning, which occurred in the DRC with the aboriginal in 1976 in Sudan and Zaire [97]. Sometime recently 2014, around more than 2400 individuals were tainted, along with more than 1500 recorded passings in the previous four decades since its first disclosure in 1976 in the zones of Zaire and Sudan [98]. From December 2013 to September 2014, aggregate of 2296 passings was accounted for out of 4507 affirmed, plausible instances of Ebola infection from five nations of West Africa i.e., Guinea, Nigeria, Senegal, Liberia, and Sierra Leone [99]. In Figure 10 clear out that the largest flare-up is the ongoing epidemic in some particular zones of West Africa, including primary targets of Guinea and Sierra Leone. WHO reported a sum of 28,665 cases watched and 11,329 passings from this flare-up by 29 June 2016. There were around 24 flare-ups of EVD; however, just seven included more than 100 cases [63, 94, 100].

pulverization as a result of its in-affectivity in outdoors. One case of its utilization as a bio - weapon is that the British speaks channel (BBC) introduced in 2015 that North Korean state media advocated the infection was made by the US Navy as a natural weapon [111]. It ought to and must startle the will of international society to coordinate and comply with up to. Projections starting at all past episodes tested that, with this exponential development price and no prompt care, collective contaminations of Ebola could ascend to a report soften wide variety up forthcoming years. Two currently, sufferers are beatific home with no cure, which indicates no adventitious for ascendancy efforts. Highly baleful and infectious nature of this virus stresses the cost for dependable diagnostic strategies. Now it is time to appearance the absolute commitment to reply to this accustomed disaster, its present and future impact.

CONCLUSION

Ebola virus ailment, is a lethal hemorrhagic fever, is often a devastating ailment in human




Figure 10: Demographics of Ebola virus

FUTURE THRUST

Ebola infection can be conceivably utilized as a natural weapon towards adversaries, yet it might also be difficult to get it ready for mass

beings as it entails the body’s vascular system and multiorgan failure. Most Ebola outbreaks have been pronounced in equatorial Africa and have remained a rationale of incredible venture and concern throughout the world owing to their excessive lethality, as immoderate as 90% and danger of unfold due to transport exportation.

The Ebola virus is noticeably contagious and because of its attainable aerosol and droplet transmissibility, it is protected in the 'category A' of bioterrorism agents. Till date, no high quality prophylaxis, anti-viral treatment, or vaccination for this fatal sickness is available; therefore, developing attention of hazard factors for Ebola contamination and appreciation protective measures which human beings can take is perhaps one of the most superb techniques to minimize human contamination and death.

ACKNOWLEDGEMENT

The authors are grateful to Sam Higginbottom Institute of Agriculture, Technology and Sciences, Allahabad for providing the facilities and support to complete the present research work.

FOOTNOTE

We declare that absence of any type of conflict to others.

REFERENCES

- [1] Taylor LH, Latham SM, Woolhouse ME, (2001), Risk factors for human disease emergence, *Philos Trans R Soc Lond B Biol Sci.* 356(1411),983-9.
- [2] Harty, R.N, (2009), No exit: Targeting the budding process to inhibit filovirus replication, *Antivir Res.* 81(3), 189.
- [3] Pattyn S, Groen GV, Jacob W, Piot P, Courteille G, (1977), Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire, *The Lancet.* 309(8011), 573-74.
- [4] Drosten C, Kummerer BM, Schmitz H, Gunther S, (2003), Molecular diagnostics of viral hemorrhagic fevers, *Antiviral Res.* 57(1-2), 61-87.
- [5] Elliott LH, Kiley MP, McCormick JB, (1985), Descriptive analysis of Ebola virus proteins, *Virology.* 147(1), 169-76.
- [6] Mbonye AK, Wamala JF, Nanyunja M, Opio A, Makumbi I, Aceng JR, (2014), Ebola viral haemorrhagic disease outbreak in West Africa- lessons from Uganda, *African Health Sciences.* 14(3), 495-501.
- [7] Miranda ME, Ksiazek TG, Retuya TJ, Khan AS, Sanchez A, Fulhorst CF, et al., (1999), Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996, *J Infect Dis.* 179 Suppl 1, S115-9.
- [8] Formenty P, Leroy EM, Epelboin A, Libama F, Lenzi M, Sudeck H, et al., (2006), Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus haemorrhagic fever in the Republic of Congo, *Clinical Infectious Diseases.* 42, 1521-26.
- [9] Mari Saez A, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Dux A, et al., (2015), Investigating the zoonotic origin of the West African Ebola epidemic, *EMBOMol Med.* 7(1), 17-23.
- [10] Burnouf, T, Seghatchian, J, (2014), Ebola virus convalescent blood products: Where we are now and where we may need to go, *Transfus Apheresis Sci.* 51(2), 120.
- [11] Feldmann, H.; Geisbert, T.W, (2011), Ebola haemorrhagic fever, *Lancet*, 377, (9768)- 849.
- [12] Frieden, T.R, Damon, Nichol, S, et al., (2014), Ebola 2014—New challenges, new global response and responsibility, *New Engl J Med.* 371(13), 1177.
- [13] Macneil, Rollin, P.E, (2012), Ebola and marburg hemorrhagic fevers: Neglected tropical diseases? , *PLoS Negl Trop Dis.* 6(6), e1546.
- [14] Muhlberger E, Lotfering B, Klenk HD, Becker S, (1998), Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes, *J Virol.* 72(11), 8756-64.
- [15] Sullivan N, Yang ZY, Nabel GJ, (2003), Ebola virus pathogenesis: implications for vaccines and therapies, *Journal of Virology.* 77(18), 9733-7.
- [16] Timmins J, Scianimanico S, Schoehn G, Weissenhorn W, (2001), Vesicular release of Ebola virus matrix protein VP40, *Virology.* 283(1), 1-6.
- [17] Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y, (2002), Ebola virus

- VP40 drives the formation of virus-like filamentous particles along with GP, *J Virol.* 76(10), 4855–65.
- [18] Olejnik J, Ryabchikova E, Corley RB, Muhlberberger E, (2011), Intracellular events and cell fate in filovirus infection, *Viruses.* 3, 1501-31.
- [19] Hoenen T, Jung S, Herwig A, Groseth A, Becker S, (2010), Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription, *Virology.* 403(1), 56–66.
- [20] Sanchez A, Trappier SG, Mahy BWJ, Peters CJ, Nichol S, (1996), The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing, *Proc Natl AcadSci USA.* 93, 3602-07.
- [21] Huang Y, Xu L, Sun Y, Nabel GJ, (2002), The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein, *Molecular Cell.* 10(2), 307–16.
- [22] Takada A, Watanabe S, Ito H, Okazaki K, Kida H, Kawaoka Y, (2000), Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry, *Virology.* 278(1), 20–6.
- [23] Takada A, Fujioka K, Tsuiji M, Morikawa A, Higashi N, Ebihara H, et al., (2004), Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry, *J Virol.* 78(6), 2943–7.
- [24] Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ, (1996), Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages, *J Virol.* 70, 2208-14.
- [25] Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, et al., (1996), Experimental inoculation of plants and animals with Ebola virus, (1996), *Emerging Infectious Diseases.* 2(4), 321-25.
- [26] Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, Whitbeck JC, et al., (2003), DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells, *Virology.* 305(1), 115–23.
- [27] Lin G, Simmons G, Pohlmann S, Baribaud F, Ni H, Leslie GJ, et al., (2003), Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DCSIGN and DC-SIGNR, *J Virol.* 77(2), 1337–46.
- [28] Ansari AA, (2014), Clinical features and pathobiology of Ebolavirus infection, *J of autoimmunity.* 55, 1-9.
- [29] Kobinger GP, Leung A, Neufeld J, Richardson JS, Falzarano D, Smith G, et al., (2011), Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs, *J Infect Dis.* 204(2), 200–8.
- [30] Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, et al., (2011), Ebola virus entry requires the cholesterol transporter Niemann-Pick C1, *Nature.* 477(7364), 340–3.
- [31] Fisher-Hoch SP, Platt GS, Neild GH, Southee T, Baskerville A, Raymond RT, et al., (1985), Pathophysiology of shock and haemorrhage in a fulminating viral infection (Ebola), *J Infect Dis.* 152(5), 887–94.
- [32] Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, et al., (2012), Ebola virus entry requires the host-programmed recognition of an intracellular receptor, *EMBO J.* 31(8), 1947–60
- [33] Gear JH, (1989), Clinical aspects of African viral haemorrhagic fevers, *Reviews of infectious diseases.* 11(Suppl 4), S777–82.
- [34] Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, MollerTank S, et al., (2011), T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus, *Proc Natl AcadSci U S A.* 108(20), 8426–31.
- [35] Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T, et al.,

- (2006), Tyro3 family mediated cell entry of Ebola and Marburg viruses, *J Virol.* 80(20), 10109–16.
- [36] Baskerville A, Fisher-Hoch SP, Neild GH, Dowsett AB, (1985), Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection, *J Pathol.* 147(3), 199-209.
- [37] Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J, (2006), Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein, *J Virol.* 80(8), 4174–8.
- [38] Jahrling PB, Geisbert TW, Geisbert JB, Swearingen JR, Bray M, Jaax NK, et al., (1999), Evaluation of immune globulin and recombinant interferon- α 2b for treatment of experimental Ebola virus infections, *J Infect Dis.* 179(Suppl 1), S224-S34.
- [39] Takahashi K, Halfmann P, Oyama M, Kozuka-Hata H, Noda T, Kawaoka Y, (2013), DNA topoisomerase 1 facilitates the transcription and replication of the Ebola virus genome, *J Virol.* 87(16), 8862–9.
- [40] Empig CJ, Goldsmith MA, (2002), Association of the caveola vesicular system with cellular entry by filoviruses. *J Virol.* 76(10), 5266–70.
- [41] Jahrling PB, Geisbert J, Swearingen JR, Jaax GP, Lewis T, Huggins JW, et al., (1996), Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses, *Arch Virol Suppl.* 11, 135-40.
- [42] Wool-Lewis RJ, Bates P, (1998), Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines, *J Virol.* 72(4), 3155–60.
- [43] Feldmann H, Nichol ST, Klenk HD, Peters CJ, Sanchez A, (1994), Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein, *Virology.* 199(2), 469–73.
- [44] Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, et al., (2007), Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys, *PLoS Pathog.* 3(1), e9.
- [45] Volchkov VE, Feldmann H, Volchkova VA, Klenk HD, (1998), Processing of the Ebola virus glycoprotein by the proprotein convertase furin, *Proc Natl Acad Sci U S A.* 95(10), 5762–7.
- [46] Kaletsky RL, Simmons G, Bates P, (2007), Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity, *J Virol.* 81(24), 13378–84
- [47] Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR, (2002), Pre and post exposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody, *J Virol.* 76, 6408-12.
- [48] Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, Nabel GJ, (2010), Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity, *J Virol.* 84(6), 2972–82.
- [49] Lee JE, Fusco ML, Hessel AJ, Oswald WB, Burton DR, Saphire EO, (2008), Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor, *Nature.* 454(7201), 177–82.
- [50] Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM, (2012), Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change, *J Virol.* 86(1), 364–72.
- [51] Jeffers SA, Sanders DA, Sanchez A, (2002), covalent modifications of the Ebola virus glycoprotein, *J Virol.* 76(24), 12463–72.
- [52] Brindley MA, Hughes L, Ruiz A, McCray PJ, Sanchez A, Sanders DA, et al., (2007), Ebola virus glycoprotein 1: identification of residues important for binding and post binding events, *J Virol.* 81(14), 7702–9.
- [53] Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST, et al., (1999), Ebola virus can be effectively neutralized by antibody produced in natural human infection, *J Virol.* 73, 6024-30.

- [54] Weissenhorn W, Carfi A, Lee KH, Skehel JJ, Wiley DC, (1998), Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain, *Mol Cell*. 2(5), 605–16.
- [55] Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ (2000), Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury, *Nat Med*. 6(8), 886–9.
- [56] Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, et al., (1999), Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients, *Nat Med*. 5, 423-26.
- [57] Kondratowicz AS, Hunt CL, Davey RA, Cherry S, Maury WJ, (2013), AMP activated protein kinase is required for the macropinocytic internalization of ebolavirus, *J Virol*. 87(2), 746–55.
- [58] Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM, (2005), Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection, *Science*. 308(5728), 1643–5.
- [59] Bradfute SB, Bavari S, (2011), correlates of immunity to Filovirus infection, *Viruses*.3, 982-1000.
- [60] Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiyama M, Sanchez A, et al., (2007), Assessment of the risk of Ebola virus transmission from bodily fluids and fomites, *J Infect Dis*. 196 Suppl 2, S142–7.
- [61] Pinzon JE, Wilson JM, Tucker CJ, Arthur R, Jahrling PB, Formenty P, (2004), Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaks, *Am J Trop Med Hyg*. 71(5), 664–74.
- [62] <https://www.cdc.gov/vhf/ebola/transmission/index.html>
- [63] <https://www.cdc.gov/vhf/ebola/about.html>
- [64] Simpson DIH, (1977), Marburg and Ebola virus infections: a guide for their diagnosis, management, and control, WHO Offset Publication. 36- 10.
- [65] Sanchez A, Ksiazek TG, Rollin PE, Miranda ME, Trappier SG, Khan AS, et al., (1999), Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates, *J Infect Dis*. 179 Suppl 1, S164–9.
- [66] Bres P, (1978), The epidemic of Ebola haemorrhagic fever in Sudan and Zaire, 1976: introductory note, *Bull World Health Organ*. 56(2), 245.
- [67] Geisbert TW, Jahrling PB, (1995), Differentiation of filoviruses by electron microscopy, *Virus Res*. 39(2-3), 129–50.
- [68] Ksiazek TG, Rollin PE, Jahrling PB, Johnson E, Dalgard DW, Peters CJ, (1992), Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates, *J Clin Microbiol*. 30(4), 947–50.
- [69] Leroy EM, Baize S, Lu CY, McCormick JB, Georges AJ, Georges-Courbot MC, et al., (2000), Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting, *J Med Virol*. 60(4), 463–7.
- [70] Kamata T, Natesan M, Warfield K, Aman MJ, Ulrich RG, (2014), Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays, *Clin Vaccine Immunol*. 21(12), 1605–12.
- [71] Daddario-diCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA, et al., (2006), Postexposure protection against Marburg haemorrhagic fever with recombinant Vesicular stomatitis virus vectors in non-human primates: an efficacy assessment, *Lancet*. 367, 1399-404.
- [72] Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, et al., (2011), Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses, *J Virol*. 85(20), 10605–16.
- [73] Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, et al., (2003), Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates, *Nature*. 424(6949), 681–84.

- [74] Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S, (2007), Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge, *J Infect Dis.* 196 Suppl2, S430–7.
- [75] Geisbert TW, Geisbert JB, Leung A, Daddario-Di Caprio KM, Hensley LE, et al., (2009), Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus, *J Virol.* 83(14), 7296–304.
- [76] Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, et al., (2008), Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections, *Clin Vaccine Immunol.* 15(3), 460–7.
- [77] Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, et al., (2008), Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Haemorrhagic Fever in Nonhuman Primates, *J Virol.* 82(11), 5664–68.
- [78] Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, et al., (2005), Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses, *Nat Med.* 11(7), 786–90.
- [79] Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, Nabel GJ, (1998), Immunization for Ebola virus infection, *Nat Med.* 4, 37-42.
- [80] Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al., (2006), VRC 204 Study Team. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase 1 clinical trial, *Clinical and vaccine immunology.* 13(11), 1267-77.
- [81] Dixon MG, Schafer IJ, (2014), Ebola viral disease outbreak–West Africa 2014, *MMWR Morb MortalWkly Rep.* 63(25), 548–51.
- [82] Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ, (2000), Development of a preventive vaccine for Ebola virus infection in primates, *Nature.* 408, 605- 09.
- [83] Salvaggio MR, Baddley JW, (2004), other viral bioweapons: Ebola and Marburg hemorrhagic fever, *DermatolClin.* 22(3), 291–302.
- [84] Geisbert TW, Hensley LE, (2004), Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions, *Expert Rev MolMed.* 6(20), 1–24.
- [85] Choi JH, Croyle MA, (2013), Emerging targets and novel approaches to Ebola virus prophylaxis and treatment, *Bio Drugs.* 27(6), 565–83.
- [86] Spickler AR, (2004), Ebolavirus and Marburgvirus Infections.
- [87] Feldmann H, Geisbert TW, (2011), Ebola haemorrhagic fever, *Lancet.* 377(9768), 849-62.
- [88] Park, D. J. et al., (2015), Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone, *Cell.* 161, 1516–1526.
- [89] Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A, (1999), Human infection due to Ebola virus, subtype Cote d’Ivoire: clinical and biologic presentation, *J Infect Dis.* 179 Suppl 1, S48–53.
- [90] Andersen, K. G. et al., (2015), Clinical sequencing uncovers origins and evolution of Lassa virus, *Cell.* 162, 738–750.
- [91] Kuhn, J. H. et al., (2014), Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014, *Viruses.* 6, 4760–4799.
- [92] Georges-Courbot MC, Lu CY, Lansoud-Soukate J, Leroy E, Baize S, (1997), Isolation and partial molecular characterisation of a strain of Ebola virus during a recent epidemic of viral haemorrhagic fever in Gabon, *Lancet.* 349(9046), 181.
- [93] Baize, S. et al., (2014), Emergence of Zaire Ebola virus disease in Guinea, *N. Engl. J. Med.* 371, 1418–1425.

- [94] Borchert M, Mutyaba I, Van Kerkhove MD, Lutwama J, Luwaga H, Bisoborwa G, et al., (2011), Ebola haemorrhagic fever outbreak in Masindi District, Uganda: outbreak description and lessons learned, *BMC Infect Dis.* 11, 357.
- [95] Kucharski, A. J. & Edmunds, W. J., (2014), Case fatality rate for Ebola virus disease in West Africa, *Lancet.* 384, 1260.
- [96] Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ, et al., (2009), Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007, *VectorBorne Zoonotic Dis.* 9(6), 723–8.
- [97] Simon-Loriere, E. et al., (2015), distinct lineages of Ebola virus in Guinea during the 2014 West African epidemic, *Nature.* 524, 102–104.
- [98] Nkoghe D, Kone ML, Yada A, Leroy E, (2011), A limited outbreak of Ebola haemorrhagic fever in Etoumbi, Republic of Congo, 2005, *Trans RSoc Trop Med Hyg.* 105(8), 466–72.
- [99] Walsh, P. D, Biek, R. & Real, L. A, (2005), Wave-like spread of Ebola Zaire, *PLoS Biol.* 3, e371.
- [100] Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ, (1999), Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit, *J Infect Dis.* 179 Suppl1, S87–91.
- [101] Drummond, A. J., Ho, S. Y., Phillips, M. J. & Rambaut, A, (2006), Relaxed phylogenetics and dating with confidence, *PLoS Biol.* 4, e88.
- [102] Georges, A. J. et al., (1999), Ebola hemorrhagic fever outbreaks in Gabon, 1994–1997: epidemiologic and health control issues, *J. Infect. Dis.* 179 Suppl 1, 65- 75.
- [103] Yozwiak, N. L. et al., (2016), Roots, not parachutes: research collaborations combat Outbreaks, *Cell.* 166, 5–8.
- [104] Baron RC, McCormick JB, Zubeir OA, (1983), Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread, *Bull WorldHealth Organ.* 61(6), 997–1003.
- [105] Guindon, S. & Gascuel, O, (2003), A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood, *Syst. Biol.* 52, 696–704.
- [106] Heymann DL, Weisfeld JS, Webb PA, Johnson KM, Cairns T, Berquist H, (1980), Ebola hemorrhagic fever: Tandala, Zaire, 1977-1978, *J Infect Dis.* 142(3), 372–6.
- [107] Poon, L. L. et al., (2016), Quantifying influenza virus diversity and transmission in humans, *Nat. Genet.* 48, 195–200.
- [108] Vogel, G, (2015), A reassuring snapshot of Ebola, *Science.* 347, 1407.
- [109] Rouquet P, Froment JM, Bermejo M, Kilbourn A, Karesh W, Reed P, et al., (2005), Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003, *Emerg Infect Dis.* 11 (2), 283–90.
- [110] Fischer, R. J, Judson, S, Miazgowiec, K, Bushmaker, T. & Munster, V. J, (2016), Ebola virus persistence in semen ex vivo, *Emerg. Infect. Dis.* 22, 289–291
- [111] Salvaggio MR, Baddley JW, (2004), other viral bioweapons: Ebola and Marburg hemorrhagic fever, *Dermatolclin.* 22(3), 291- 302.